Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Fig. 3

A Swimmer plot for the exposure and response duration of rezivertinib in FAS. As per the protocol and the RECIST version 1.1, after the patient’s disease progression, the patient may continue the treatment if investigators considered the patient would still benefit from the study treatment. In patients with a BICR-assessed confirmed objective response, the time when the objective response was first observed is indicated by an × , and the time when the objective response was terminated is indicated by a circle. B Spider plot for BICR-assessed percentage change of tumor size from baseline at different time points. Abbreviation: BICR, blinded independent central review; PR, partial response; SD, stable disease; PD, progressive disease; FAS, full analysis set; RECIST: Response Evaluation Criteria in Solid Tumors

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us